Friday Courses
Receive in-depth updates on the latest in GI and hepatology, endoscopy, and practice management when you attend one or more of the optional Friday courses. Six courses are offered: five half-day courses, the GI Pathophysiology Course, the What’s New in GI Pharmacology Course, the Practice Management Summit, and the ACG Advanced Practice Provider Leadership Summit; one evening course, the Guide to the Guidelines Course; and one full-day course, the ACG/ASGE Endoscopy Course.
What’s New in GI Pharmacology Course
Friday, October 24, 2025 | 7:55 am – 11:45 am Mountain Time
Course Directors: Brooks D. Cash, MD, FACG, and Shailja C. Shah, MD, MPH
| Friday, October 24, 2025 │ ALL TIMES ARE LISTED IN MOUNTAIN TIME (MT) | |
|---|---|
| 7:55 am | Welcome and Introductions Brooks D. Cash, MD, FACG, and Shailja C. Shah, MD, MPH |
| SESSION 1 Moderator: Brooks D. Cash, MD, FACG |
|
| 8:00 am | Royal Flush: 2025 Update on Best Practices for Colonoscopy Bowel Preparation Carol A. Burke, MD, MACG Discuss the mechanisms, evidence, and positioning of bowel preparation strategies and updated recommendations. |
| 8:20 am | Alphabet Soup: PCABs vs PPIs in Acid-Related GI Disorders: How Do I Choose the Best Option for My Patient? Shailja C. Shah, MD, MPH Describe the differences in mechanism of action and clinical effects between potassium competitive acid-blocking medications and proton pump inhibitors and apply these differences in patient care to improve outcomes. |
| 8:40 am | Positioning Pharmacologic Therapies in Crohn’s Disease: A 2025 Update David T. Rubin, MD, FACG Explain the evidence and placement of current and future pharmacologic therapies for Crohn’s disease. |
| 9:00 am | Positioning Pharmacologic Therapies in Ulcerative Colitis: A 2025 Update Millie D. Long, MD, MPH, FACG Discuss the evidence and placement of current and future pharmacologic therapies for ulcerative colitis. |
| 9:20 am | Q & A |
| 9:40 am | Break |
| SESSION 2 Moderator: Shailja Shah, MD, MPH |
|
| 10:00 am | Friend vs Foe: Cannabis and Cannabinoids as Instigators and Ameliorators in Gastrointestinal Diseases Christopher D. Velez, MD Identify the role of cannabinoid receptors and agents targeting those receptors as causes and treatments of gastrointestinal symptoms. |
| 10:20 am | What’s in a Name? Pharmacologic Therapies for MASLD in 2025: When to Start, What to Start, and How to Monitor? Joseph K. Lim, MD, FACG Identify currently available and emerging management strategies for patients with metabolic dysfunction-associated steatotic liver disease. |
| 10:40 am | Keep on Running: Pharmacologic Therapies for Chronic Diarrhea in Patients With Native vs Postsurgical Anatomy Brooks D. Cash, MD, FACG Explain the evaluation and management of chronic diarrhea in patients with and without a history of gastrointestinal surgery. |
| 11:00 am | It’s Not Easy Being Queasy: Pharmacologic Therapies for Chronic Nausea Brian E. Lacy, MD, PhD, FACG Describe the current best evidence regarding the evaluation and management of patients with chronic nausea, with special focus on patients diagnosed with POTS and EDS. |
| 11:20 am | Q & A |
| 11:45 am | Course Adjourns |
